Angelman syndrome is a genetic disorder that causes developmental delay and neurological problems. Infants appear typical at birth but often have feeding problems and exhibit developmental delays by 6 to 12 months. Seizures often begin between 2 and 3 years of age. Speech impairment is pronounced. Individuals often display hyperactivity, small head size, sleep disorders, and movement and balance disorders. Angelman syndrome results from absence of a functional copy of the UBE3A gene inherited from the mother. There is no specific therapy for Angelman syndrome. Medical therapy for seizures is usually necessary. Physical and occupational therapies, communication therapy, and behavioral therapies are important in allowing individuals to reach their maximum developmental potential.
People related to the topic: Angelman syndrome
Roger Colbran, Ph.D.
Louise B. McGavock Chair and Professor of Molecular Physiology and Biophysics
Elisabeth Dykens, Ph.D.
Professor of Psychology, Psychiatry & Behavioral Sciences, and Pediatrics
Kevin Haas, Ph.D., M.D.
Assistant Professor of Neurology
Rachel Hundley, Ph.D.
Assistant Professor of Pediatrics, Division of Developmental Medicine, and Psychiatry & Behavioral Sciences; Director, Vanderbilt Kennedy Center Learning Assessment Clinic
Sarika Peters, Ph.D.
Associate Professor of Pediatrics and Psychiatry & Behavioral Sciences; Director, IDDRC Behavioral Phenotyping Core (Core D)
Back to the topic index